Electrical Stimulation for Alzheimer's Disease
Alzheimer's Disease (AD) is the most common type of dementia, whose symptomology consists of memory loss, poor judgment, and difficulty completing familiar tasks. In AD, neurons are subjected to cell death, destroying the connectivity of various brain regions. The most prominent region accessible through non-invasive stimulation is the forceps minor — a commissural fiber connecting homologous regions in the frontal lobe, highly associated with decision-making, language skills, and emotional regulation. U sends packets of electrical stimuli down these tracts to alleviate AD symptoms.
12-Week am-tPRNS Intervention Results
Our 12-week amplitude-modulated am-tPRNS intervention produced significant changes in brain connectivity patterns in Alzheimer's disease patients, measured via advanced fMRI analysis.
Local & Interhemispheric Connectivity Changes
LCOR — Local Synchronization
Integrated local correlation (LCOR) analysis, which measures local synchronization of brain activity, revealed increased local synchronization by over 200%in key regions including the frontal pole, hippocampus, and temporal areas. The hippocampus is the brain's primary memory center and one of the first regions destroyed by Alzheimer's pathology. A 200%+ increase in hippocampal synchronization represents a meaningful signal of restored neural activity in a region most critical to memory formation and recall.
IHC — Interhemispheric Coherence
Interhemispheric coherence (IHC) results showed enhanced coordination between hemispheres by up to 410% in structures critical for memory and emotional regulation.
MCOR — Multivariate Connectivity
Multivariate correlation (MCOR) findings demonstrated the emergence of new connections within frontal, temporal, and subcortical networks, with voxel increases ranging from 115% to 5,400%.
“These changes suggest that am-tPRNS may strengthen residual neural pathways and promote beneficial neuroplastic responses in brain areas affected by Alzheimer's disease pathology.”
Investigational Device Notice: Axis is an investigational medical device and is not cleared by the FDA for commercial distribution. Subjects in research studies participated under IRB approval or equivalent medical oversight.
Interested in Our Alzheimer's Research?
Join our waitlist for clinical trial updates, or explore Axis, our investigational electrical stimulation device for Alzheimer's disease.